AG
ASND icon

Advisor Group’s Ascendis Pharma A/S ASND Stock Holding History

Advisor Group’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$14K Buy
103
+3
+3% +$333 ﹤0.01% 4134
2019
Q3 		$10K Hold
100
– – ﹤0.01% 4327
2019
Q2 		$12K Hold
100
– – ﹤0.01% 4251
2019
Q1 		$12K Hold
100
– – ﹤0.01% 4259
2018
Q4 		$6K Hold
100
– – ﹤0.01% 4417
2018
Q3 		$7K Buy
+100
New +$6.88K ﹤0.01% 4436

Other funds holding ASND

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Advisor Group's ASND Position: Q4 2019 in Review

Advisor Group increased its Ascendis Pharma A/S (ASND) stake by 3% in Q4 2019, buying an estimated $333 and bringing the position to 103 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #4134.

Advisor Group first reported a position in ASND in Q3 2018 and has held it in 6 quarters since. 143 funds tracked by Wall St. Rank hold ASND as of Q4 2019.

  • Advisor Group held 103 shares of Ascendis Pharma A/S worth $14K as of Q4 2019.
  • Advisor Group bought 3 Ascendis Pharma A/S shares in Q4 2019, an estimated $333.
  • Ascendis Pharma A/S made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4134 holding.
  • Advisor Group first reported a position in Ascendis Pharma A/S in Q3 2018 and has held it in 6 quarters since.
  • 143 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.